M Auerbach

Summary

Publications

  1. doi request reprint The role of intravenous iron in anemia management and transfusion avoidance
    Michael Auerbach
    Private Practice, Baltimore, Maryland, USA
    Transfusion 48:988-1000. 2008
  2. doi request reprint Clinical use of intravenous iron: administration, efficacy, and safety
    Michael Auerbach
    Georgetown University School of Medicine, Washington, DC, USA
    Hematology Am Soc Hematol Educ Program 2010:338-47. 2010
  3. doi request reprint Intravenous iron as standard of care in oncology: opportunity lost
    Michael Auerbach
    Georgetown University, Washington, DC, USA
    J Am Pharm Assoc (2003) 48:455-7. 2008
  4. ncbi request reprint Intravenous iron in oncology
    Michael Auerbach
    Georgetown University, Washington, DC, USA
    J Natl Compr Canc Netw 6:585-92; quiz 592. 2008
  5. doi request reprint Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease
    M Auerbach
    Auerbach Hematology and Oncology, Baltimore, Maryland 21237, USA
    Kidney Int 73:528-30. 2008
  6. doi request reprint Intravenous iron: from anathema to standard of care
    Michael Auerbach
    Division of Hematology and Oncology, Private Practice Baltimore Maryland, Clinical Professor of Medicine, Georgetown University School of Medicine, Washington, DC, USA
    Am J Hematol 83:580-8. 2008
  7. ncbi request reprint Clinical update: intravenous iron for anaemia
    Michael Auerbach
    Auerbach Haematology and Oncology, Georgetown University School of Medicine, Baltimore, MD 21237, USA
    Lancet 369:1502-4. 2007
  8. ncbi request reprint Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial
    Michael Auerbach
    Averbach Hematology Oncology, Baltimore, MD, USA
    J Clin Oncol 22:1301-7. 2004
  9. ncbi request reprint A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients
    M Auerbach
    Franklin Square Hospital Center and Johns Hopkins Bayview Medical Center, Baltimore, MD 21237 3998, USA
    Am J Kidney Dis 31:81-6. 1998
  10. ncbi request reprint Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial
    M Auerbach
    Franklin Square Hospital Center, Baltimore, Maryland, USA
    J Lab Clin Med 131:257-60. 1998

Detail Information

Publications18

  1. doi request reprint The role of intravenous iron in anemia management and transfusion avoidance
    Michael Auerbach
    Private Practice, Baltimore, Maryland, USA
    Transfusion 48:988-1000. 2008
  2. doi request reprint Clinical use of intravenous iron: administration, efficacy, and safety
    Michael Auerbach
    Georgetown University School of Medicine, Washington, DC, USA
    Hematology Am Soc Hematol Educ Program 2010:338-47. 2010
    ..The potential advantages of total dose infusion (TDI), complete repletion in a single setting, are highlighted. A new paradigm for iron replacement therapy in iron deficiency anemia is presented...
  3. doi request reprint Intravenous iron as standard of care in oncology: opportunity lost
    Michael Auerbach
    Georgetown University, Washington, DC, USA
    J Am Pharm Assoc (2003) 48:455-7. 2008
  4. ncbi request reprint Intravenous iron in oncology
    Michael Auerbach
    Georgetown University, Washington, DC, USA
    J Natl Compr Canc Netw 6:585-92; quiz 592. 2008
    ..This article presents evidence recommending routine incorporation of IV Fe into treatment for CIA...
  5. doi request reprint Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease
    M Auerbach
    Auerbach Hematology and Oncology, Baltimore, Maryland 21237, USA
    Kidney Int 73:528-30. 2008
    ..Administration of iron salts to pre-dialysis patients with chronic kidney disease may not be optimal. We recommend the total dose infusion of low molecular weight iron dextran as an option for iron replacement...
  6. doi request reprint Intravenous iron: from anathema to standard of care
    Michael Auerbach
    Division of Hematology and Oncology, Private Practice Baltimore Maryland, Clinical Professor of Medicine, Georgetown University School of Medicine, Washington, DC, USA
    Am J Hematol 83:580-8. 2008
    ..Intravenous iron has been shown to overcome hepcidin induced iron restricted erythropoiesis in iron-replete patients. Available clinical and experimental data suggest that increased utilization of intravenous iron should be considered...
  7. ncbi request reprint Clinical update: intravenous iron for anaemia
    Michael Auerbach
    Auerbach Haematology and Oncology, Georgetown University School of Medicine, Baltimore, MD 21237, USA
    Lancet 369:1502-4. 2007
  8. ncbi request reprint Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial
    Michael Auerbach
    Averbach Hematology Oncology, Baltimore, MD, USA
    J Clin Oncol 22:1301-7. 2004
    ..Intravenous (IV) iron improves hemoglobin (Hb) response and decreases dosage requirements in patients with anemia of kidney disease, but its effect has not been studied in randomized trials in cancer patients...
  9. ncbi request reprint A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients
    M Auerbach
    Franklin Square Hospital Center and Johns Hopkins Bayview Medical Center, Baltimore, MD 21237 3998, USA
    Am J Kidney Dis 31:81-6. 1998
    ..Total-dose intravenous iron dextran infusion is safe, convenient, less expensive, and as efficacious as divided-dose infusions...
  10. ncbi request reprint Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial
    M Auerbach
    Franklin Square Hospital Center, Baltimore, Maryland, USA
    J Lab Clin Med 131:257-60. 1998
    ..These data demonstrate that administration of MP before and after TDI reduces the frequency and severity of the arthralgia-myalgia syndrome. We conclude that 125 mg i.v. MP should be given routinely before and after TDI of iron dextran...
  11. doi request reprint Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia
    Michael Auerbach
    Auerbach Hematology Oncology Associates, 9110 Philadelphia Road, Baltimore, MD 21237, USA
    Am J Hematol 85:655-63. 2010
    ..Transient anaphylactoid reactions were reported in two patients receiving IV iron. Darbepoetin alfa at 300 μg Q3W and 500 μg Q3W showed similar benefit, while added IV iron improved treatment response in these patients...
  12. ncbi request reprint Ferumoxytol as a new, safer, easier-to-administer intravenous iron: yes or no?
    Michael Auerbach
    Am J Kidney Dis 52:826-9. 2008
  13. ncbi request reprint Should intravenous iron be the standard of care in oncology?
    Michael Auerbach
    J Clin Oncol 26:1579-81. 2008
  14. ncbi request reprint High-molecular weight iron dextran: a wolf in sheep's clothing?
    George M Rodgers
    J Am Soc Nephrol 19:833-4. 2008
  15. ncbi request reprint Iron and the anaemia of chronic disease: a review and strategic recommendations
    Ivor Cavill
    Medical School, Cardiff University, UK
    Curr Med Res Opin 22:731-7. 2006
    ..A focused literature search was conducted after key issues had been identified. A series of recommendations was agreed, backed, wherever possible, by published evidence which is included in the annotations...
  16. ncbi request reprint Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy
    David H Henry
    Joan Karnell Cancer Center, Pennsylvania Hospital, 230 West Washington Square, Philadelphia, PA 19106, USA
    Oncologist 12:231-42. 2007
    ..To evaluate the safety and efficacy of intravenous (IV) sodium ferric gluconate complex (FG), oral ferrous sulfate, or no iron to increase hemoglobin (Hb) in anemic cancer patients receiving chemotherapy and epoetin alfa...
  17. ncbi request reprint Intravenous iron
    Michael Auerbach
    N Engl J Med 357:93-4. 2007
  18. ncbi request reprint Increased importance of intravenous iron in chemotherapy-induced anemia
    Michael Auerbach
    J Clin Oncol 25:2145-6. 2007